Using the co-expression of TOX genes to evaluate the OS, we found that lower OS was observed in TOX2highTOX4high AML patients in comparison with TOX2highTOX4low or TOX2lowTOX4high AML patients and TOX2lowTOX4low AML patients (3-year OS: 0% vs. 25% vs. 56%, P = 0.002, Figure 4A). Here, TOX is linked to acute myeloid leukemia.